Disease · MONDO_0019944

Eisenmenger syndrome

6 sourcesdiseases-2026-09-18-0.1.0

Cite this record

ConductScience Library. Eisenmenger syndrome. Diseases, record MONDO_0019944. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0019944

On this page

Disease

Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.

Name: Eisenmenger syndrome; Open Targets
Open Targets ID: MONDO_0019944; Open Targets
Other names: ES, Eisenmenger's syndrome; Open Targets
MeSH: D004541; MeSH
NCI Thesaurus: C84390; NCI Thesaurus
Orphanet: ORPHA:97214; Orphanet
Highest stage of its drugs: Phase 3, for 3 of its 6 drugs, from ClinicalTrials.gov; Open Targets

Drugs6

The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.

Drug	ChEMBL ID	Type	Open Targets' stage	Stage reported by	Reports	Of them trials	Trials shown here	Source
MACITENTAN	CHEMBL2103873	Small molecule	Phase 3	ClinicalTrials.gov	2	2	2	Drugs and targets
SILDENAFIL	CHEMBL192	Small molecule	Phase 3	ClinicalTrials.gov	2	2	2	Drugs and targets
BOSENTAN	CHEMBL957	Small molecule	Phase 3	ClinicalTrials.gov	1	1	1	Drugs and targets
SOTATERCEPT	CHEMBL1743073	Protein	Phase 2	ClinicalTrials.gov	1	1	1	Drugs and targets
TADALAFIL	CHEMBL779	Small molecule	Phase 2	ClinicalTrials.gov	1	1	1	Drugs and targets
PENTOXIFYLLINE	CHEMBL628	Small molecule	Unknown	ClinicalTrials.gov	1	1	1	Drugs and targets

Targets28

The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.

Target	Protein	Its drugs that act on it	Mechanisms	Highest stage of those drugs	Gene in Genes	Source
PDE5A	3',5'-cyclic phosphodiesterase	3	3',5'-cyclic phosphodiesterase inhibitor; Phosphodiesterase 5A inhibitor	Phase 3	https://conductscience.org/library/genes/8654	Drugs and targets
EDNRA	Endothelin receptor, ET-A/ET-B	2	Endothelin receptor, ET-A/ET-B antagonist	Phase 3	https://conductscience.org/library/genes/1909	Drugs and targets
EDNRB	Endothelin receptor, ET-A/ET-B	2	Endothelin receptor, ET-A/ET-B antagonist	Phase 3	https://conductscience.org/library/genes/1910	Drugs and targets
ADORA2A	Adenosine A2 receptor	1	Adenosine A2 receptor antagonist	Unknown	https://conductscience.org/library/genes/135	Drugs and targets
ADORA2B	Adenosine A2 receptor	1	Adenosine A2 receptor antagonist	Unknown	https://conductscience.org/library/genes/136	Drugs and targets
INHBA	Inhibin beta A chain	1	Inhibin beta A chain inhibitor	Phase 2	https://conductscience.org/library/genes/3624	Drugs and targets
PDE10A	3',5'-cyclic phosphodiesterase	1	3',5'-cyclic phosphodiesterase inhibitor	Unknown	https://conductscience.org/library/genes/10846	Drugs and targets
PDE1A	3',5'-cyclic phosphodiesterase	1	3',5'-cyclic phosphodiesterase inhibitor	Unknown	https://conductscience.org/library/genes/5136	Drugs and targets
PDE1B	3',5'-cyclic phosphodiesterase	1	3',5'-cyclic phosphodiesterase inhibitor	Unknown	https://conductscience.org/library/genes/5153	Drugs and targets
PDE1C	3',5'-cyclic phosphodiesterase	1	3',5'-cyclic phosphodiesterase inhibitor	Unknown	https://conductscience.org/library/genes/5137	Drugs and targets

1 to 10 of 28

See all 28 targets

Trials7

Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs.

Trial	Title	Phase	Participants	Results first posted	Conditions	Drugs	Linked by	Source
NCT01743001	Clinical Study to Evaluate the Effects of Macitentan on Exercise Capacity in Subjects With Eisenmenger Syndrome	Phase 3	226	2018-01-30	Pulmonary Arterial Hypertension	MACITENTAN	Its record names the disease	ClinicalTrials.gov
NCT01739400	Clinical Study to Assess the Long-term Safety, Tolerability, and Efficacy of Macitentan in Subjects With Eisenmenger Syndrome	Phase 3	217	2019-04-16	Pulmonary Arterial Hypertension	MACITENTAN	Its record names the disease	ClinicalTrials.gov
NCT05611268	Pentoxifylline as an Adjunct Therapy for Patients With Eisenmenger Syndrome	Not applicable	48		Eisenmenger Syndrome	PENTOXIFYLLINE	Its record names the disease	ClinicalTrials.gov
NCT07498803	Sota-ES - Sotatercept in Patients With Congenital Heart Disease and Eisenmenger´s Syndrome	Phase 2	40		Congenital Heart Disease (CHD), Eisenmenger Syndrome, PAH	SOTATERCEPT	Its record names the disease	ClinicalTrials.gov
NCT01200732	Phosphodiesterase-5 Inhibitor in Eisenmenger Syndrome	Phase 2	28		Eisenmenger Syndrome	TADALAFIL	Its record names the disease	ClinicalTrials.gov
NCT00586794	Therapy of Pulmonary Arterial Hypertension (PAH) - Treatment With Sildenafil in Eisenmenger Patients	Phase 3	24		Pulmonary Arterial Hypertension (PAH)	SILDENAFIL	Its record names the disease	ClinicalTrials.gov
NCT00303004	Combination Treatment With Bosentan and Sildenafil to Patients With Eisenmengers Syndrome	Phase 3	20		Eisenmenger Syndrome	BOSENTAN, SILDENAFIL	Its record names the disease	ClinicalTrials.gov

Comparisons in its trials2

Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.

Comparison	Group 1, with the outcome	Group 2, with the outcome	Participants	Trial	Source
Macitentan vs Placebo: deaths from any cause	1 of 114	0 of 112	226	NCT01743001	Trial comparisons
Macitentan vs Placebo: serious adverse events	7 of 114	2 of 112	226	NCT01743001	Trial comparisons

Papers from its trials3

The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.

PMID	Listed as	Trials listing it	Source
30586694	DERIVED	1	PubMed
21914136	DERIVED	1	PubMed
20202971	DERIVED	1	PubMed

Data dates

The date of each source this release read.

Open Targets: 2026-09-18; Open Targets
Drug links and their checks, from Drugs and targets: 2026-09-18; Drugs and targets
ClinicalTrials.gov, from Trials: 2026-11-12; Trials
Comparisons, from Trial comparisons: 2026-03-23; Trial comparisons
PubMed, for the checks: 2026-11-06; PubMed
MeSH, for the checks: 2026-11-10; MeSH

Sources 6

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ChEMBL, through Open TargetsCC BY-SA 3.0
ClinicalTrials.govNo license stated
NLM's MeSHNLM's terms
Open TargetsCC0 1.0
PubMedNLM's terms

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
ClinicalTrials.govnone stated
NLM's MeSHNLM's
Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
PubMedNLM's terms

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this disease from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/diseases/v1/MONDO_0019944

GET https://conductscience.org/api/diseases/v1/MONDO_0019944/targets?page=2

API reference For AI assistants